Pictet Asset Management Holding SA boosted its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 514,540 shares of the company’s stock after purchasing an additional 22,472 shares during the period. Pictet Asset Management Holding SA owned 0.59% of Abivax worth $50,949,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of ABVX. Eversept Partners LP increased its position in shares of Abivax by 42.0% during the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock worth $104,048,000 after purchasing an additional 276,589 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Abivax by 31.6% in the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after buying an additional 211,068 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Abivax by 40.9% in the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock valued at $81,923,000 after buying an additional 213,440 shares during the last quarter. Two Seas Capital LP bought a new position in shares of Abivax in the third quarter valued at $66,996,000. Finally, Orbimed Advisors LLC grew its stake in shares of Abivax by 26.6% in the first quarter. Orbimed Advisors LLC now owns 465,700 shares of the company’s stock valued at $51,856,000 after buying an additional 97,800 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.
Abivax Trading Up 3.4%
Shares of NASDAQ ABVX opened at $90.00 on Wednesday. Abivax SA Sponsored ADR has a 12 month low of $69.81 and a 12 month high of $148.83. The stock has a 50 day moving average of $96.24 and a 200-day moving average of $112.99. The company has a market capitalization of $7.88 billion, a P/E ratio of -14.85 and a beta of 1.36.
Abivax (NASDAQ:ABVX – Get Free Report) last posted its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.80 million. Analysts predict that Abivax SA Sponsored ADR will post -4.14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Abivax in a research report on Wednesday, October 21st. Guggenheim reissued a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research report on Tuesday, October 20th. Morgan Stanley reissued an “overweight” rating and issued a $180.00 price objective on shares of Abivax in a research report on Friday, July 24th. Wedbush lowered their price objective on shares of Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Abivax in a report on Wednesday, September 9th. They issued a “buy” rating and a $155.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Abivax currently has a consensus rating of “Moderate Buy” and a consensus price target of $155.00.
Get Our Latest Research Report on ABVX
About Abivax
Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.
Recommended Stories
- Five stocks we like better than Abivax
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
